What is prochlorperazine used for?

Indications and Usage, quoted from the label by Jubilant Cadista Pharmaceuticals Inc. (ANDA040268). Cross-references to other label sections are left out.

For control of severe nausea and vomiting. For the treatment of schizophrenia. Prochlorperazine is effective for the short-term treatment of generalized non-psychotic anxiety. However, prochlorperazine is not the first drug to be used in therapy for most patients with non-psychotic anxiety, because certain risks associated with its use are not shared by common alternative treatments (e.g., benzodiazepines). When used in the treatment of non-psychotic anxiety, prochlorperazine should not be administered at doses of more than 20 mg per day or for longer than 12 weeks, because the use of prochlorperazine at higher doses or for longer intervals may cause persistent tardive dyskinesia that may prove irreversible (see WARNINGS ). The effectiveness of prochlorperazine as treatment for non-psychotic anxiety was established in 4-week clinical studies of outpatients with generalized anxiety disorder. This evidence does not predict that prochlorperazine will be useful in patients with other non-psychotic conditions in which anxiety, or signs that mimic anxiety, are found (e.g., physical illness, organic mental conditions, agitated depression, character pathologies, etc.). Prochlorperazine has not been shown effective in the management of behavioral complications in patients with mental retardation.

Source: DailyMed label, set id b05bc20e-cd19-ab40-1ad0-84a115d6d69e, version 9, effective December 5, 2025. NDC 59746-113, one of 39 listings for this product.

Indications and Usage, quoted from the label by Amneal Pharmaceuticals NY LLC (ANDA216598). Cross-references to other label sections are left out.

For control of severe nausea and vomiting.

For the treatment of schizophrenia.

Prochlorperazine maleate tablets are effective for the short-term treatment of generalized non-psychotic anxiety. However, prochlorperazine maleate tablets are not the first drug to be used in therapy for most patients with non-psychotic anxiety, because certain risks associated with its use are not shared by common alternative treatments (e.g., benzodiazepines).

When used in the treatment of non-psychotic anxiety, prochlorperazine maleate tablets should not be administered at doses of more than 20 mg per day or for longer than 12 weeks, because the use of prochlorperazine maleate tablets at higher doses or for longer intervals may cause persistent tardive dyskinesia that may prove irreversible (see WARNINGS ).

The effectiveness of prochlorperazine maleate tablets as treatment for non-psychotic anxiety was established in 4-week clinical studies of outpatients with generalized anxiety disorder. This evidence does not predict that prochlorperazine maleate tablets will be useful in patients with other non-psychotic conditions in which anxiety, or signs that mimic anxiety, are found (e.g., physical illness, organic mental conditions, agitated depression, character pathologies, etc.).

Prochlorperazine maleate tablets have not been shown effective in the management of behavioral complications in patients with mental retardation.

Source: DailyMed label, set id a2a48790-0634-4b46-b362-98b7c252836f, version 7, effective April 9, 2026. NDC 60219-2038, one of 24 listings for this product.

Indications and Usage, quoted from the label by Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc. (ANDA204147). Cross-references to other label sections are left out.

To control severe nausea and vomiting. For the treatment of schizophrenia.

Prochlorperazine has not been shown effective in the management of behavioral complications in patients with mental retardation.

Source: DailyMed label, set id 0dc48e66-6081-421b-952b-4867c9c4c794, version 15, effective March 11, 2025. NDC 23155-294, one of 17 listings for this product.